Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
The Fred Hutchinson Cancer Research Center , is one of the world’s leading cancer research institutes. Its interdisciplinary scientists research the prevention, early detection, and treatment of cancer and other diseases in the laboratory and at patient bedside in the United States and other countries.Fred Hutch's mission statement is "the elimination of cancer and related diseases as causes of human suffering and death". Wikipedia.
Fred Hutchinson Cancer Research Center | Date: 2016-03-28
The present invention provides methods of stimulating angiogenesis and the growth or migration of cells associated with angiogenesis, by contacting animals, tissues, or cells with sulfide, alone or in combination with nitric oxide. These methods may be used for a variety or purposes, including promoting wound healings, increasing blood flow, and for the treatment and prevention of diseases and disorders associated with decreased blood flow, including ischemic or hypoxic injury.
Fred Hutchinson Cancer Research Center | Date: 2017-05-10
Chlorotoxin variants, chlorotoxin variant conjugates, compositions that include the chlorotoxin variants or conjugates, and methods for using the chlorotoxin variants, conjugates, and compositions. In particular, conjugates comprising a chlorotoxin variant where lysine K15 and/or lysine K23 are substituted by other amino acids, coupled to a fluorescent label.
Fred Hutchinson Cancer Research Center | Date: 2017-06-14
The present disclosure provides high affinity and enhanced affinity T cell receptors specific for human Wilms tumor protein 1 (WT 1) epitopes for use in treating diseases or disorders, such as cancer cells that overexpress WT-1.
Adaptive Biotechnologies Corporation and Fred Hutchinson Cancer Research Center | Date: 2017-02-22
A relative representation of adaptive immune cells in a biological sample is quantified using multiplex PCR and sequencing of adaptive immune cells, control genes, and synthetic template molecules. Disclosed herein are methods for quantifying a number of adaptive immune cells in a biological sample, and methods for quantifying a relative representation of adaptive immune cells in a biological sample that comprises a mixture of cells comprising adaptive immune cells and cells that are not adaptive immune cells. Methods are provided for amplifying by multiplex PCR and sequencing a first set of synthetic templates each comprising one TCR or IgV segment and one TCR of Ig J or C segment and a unique bar code.
Fred Hutchinson Cancer Research Center, University of Rochester and Leiden University | Date: 2017-01-25
Embodiments provide methods and compositions related to determining or predicting the presence or risk of developing DUX-4-related diseases such as muscular dystrophy. In particular, methods and compositions may be provided by identifying patients with Facioscapulohumeral muscular dystrophy (FSHD). Methods and compositions are based, in part, on the discovery that expression of certain biomarkers in patients or subjects can determine the presence or risk of developing DUX-4-related diseases such as muscular dystrophy, or particularly FSHD. Further disclosed are DUX-4 biomarkers that can be used for the methods.
Fred Hutchinson Cancer Research Center, Leiden University and University of Rochester | Date: 2017-07-19
The invention provides an agent capable of inhibiting or suppressing the level of DUX4-fl expression in a population of cells in a mammalian subject, for use in a method of treating a mammalian subject suffering from, or at risk for developing, Facioscapulohumeral Dystrophy (FSHD), wherein the agent is a nucleic acid.
Fred Hutchinson Cancer Research Center | Date: 2017-08-09
The present disclosure provides compositions, kits, and methods to protect organs by inducing acquired cytoresistance without causing injury to the organ. The compositions, kits, and methods utilize heme proteins, iron and/or vitamin B12 and, optionally, agents that impact heme protein metabolism.
Houghton A.M.,Fred Hutchinson Cancer Research Center
Nature Reviews Cancer | Year: 2013
Numerous epidemiological studies have consistently linked the presence of chronic obstructive pulmonary disease (COPD) to the development of lung cancer, independently of cigarette smoking dosage. The mechanistic explanation for this remains poorly understood. Progress towards uncovering this link has been hampered by the heterogeneous nature of the two disorders: each is characterized by multiple sub-phenotypes of disease. In this Review, I discuss the nature of the link between the two diseases and consider specific mechanisms that operate in both COPD and lung cancer, some of which might represent either chemopreventive or chemotherapeutic targets. © 2013 Macmillan Publishers Limited. All rights reserved.
Ghajar C.M.,Fred Hutchinson Cancer Research Center
Nature Reviews Cancer | Year: 2015
Despite considerable advancements that shattered previously held dogmas about the metastatic cascade, the evolution of therapies to treat metastatic disease has not kept up. In this Opinion article, I argue that, rather than waiting for metastases to emerge before initiating treatment, it would be more effective to target metastatic seeds before they sprout. Specifically, I advocate directing therapies towards the niches that harbour dormant disseminated tumour cells to sensitize them to cytotoxic agents. Treatment sensitization, achieved by disrupting reservoirs of leukaemic stem cells and latent HIV, argues that this approach, although unconventional, could succeed in improving patient survival by delaying or even preventing metastasis. © 2015 Macmillan Publishers Limited. All rights reserved.
Maloney D.G.,Fred Hutchinson Cancer Research Center
New England Journal of Medicine | Year: 2012
A 62-year-old man is evaluated for abdominal pain. Computed tomography (CT) shows a 7-cm mesenteric mass. An incisional biopsy reveals a diffuse large B-cell lymphoma, and immunohistochemical staining is positive for the B-cell antigen CD20. The patient is referred to an oncologist. A positron-emission tomographic-CT (PET-CT) scan reveals involvement of additional nodes in the lower chest and abdomen. The serum level of lactate dehydrogenase is twice the upper limit of the normal range. The results of bone marrow biopsy and aspiration are normal on pathological analysis and flow cytometry. The patient reports an unintentional weight loss of 111/2 kg (25 lb) during the previous 6 months but no unexplained fevers or night sweats. He has no history of cardiac disease, and an echocardiogram shows a normal left ventricular ejection fraction. The oncologist recommends treatment with the anti-CD20 monoclonal antibody rituximab in combination with a chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Copyright © 2012 Massachusetts Medical Society.